X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (68) 68
oncology (60) 60
male (58) 58
female (57) 57
middle aged (55) 55
aged (52) 52
index medicus (48) 48
adult (42) 42
chemotherapy (35) 35
lung neoplasms - drug therapy (30) 30
treatment outcome (30) 30
survival (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
carcinoma, non-small-cell lung - drug therapy (28) 28
aged, 80 and over (25) 25
cancer (23) 23
lung neoplasms - pathology (22) 22
neoplasm staging (21) 21
antineoplastic agents - therapeutic use (19) 19
hematology, oncology and palliative medicine (19) 19
lung neoplasms - mortality (19) 19
carcinoma, non-small-cell lung - mortality (17) 17
clinical trials (17) 17
disease-free survival (17) 17
carcinoma, non-small-cell lung - pathology (16) 16
lung cancer, non-small cell (16) 16
metastasis (16) 16
care and treatment (15) 15
antineoplastic combined chemotherapy protocols - adverse effects (14) 14
bevacizumab (14) 14
double-blind method (14) 14
kaplan-meier estimate (14) 14
lung cancer (14) 14
survival rate (14) 14
antineoplastic agents (13) 13
prognosis (13) 13
respiratory system (13) 13
survival analysis (13) 13
mutation (12) 12
research (12) 12
antimitotic agents (11) 11
carboplatin (11) 11
cisplatin (11) 11
combination (10) 10
erlotinib (10) 10
therapy (10) 10
trial (10) 10
analysis (9) 9
antibodies, monoclonal - administration & dosage (9) 9
drug therapy (9) 9
follow-up studies (9) 9
gemcitabine (9) 9
medical colleges (9) 9
neoplasm metastasis (9) 9
oncology, experimental (9) 9
quality of life (9) 9
adenocarcinoma - drug therapy (8) 8
cancer therapies (8) 8
docetaxel (8) 8
gefitinib (8) 8
oxaliplatin (8) 8
pemetrexed (8) 8
quinazolines - therapeutic use (8) 8
antineoplastic agents - adverse effects (7) 7
carcinoma (7) 7
colorectal cancer (7) 7
colorectal neoplasms - drug therapy (7) 7
deoxycytidine - analogs & derivatives (7) 7
double-blind (7) 7
guanine - analogs & derivatives (7) 7
iii trial (7) 7
leucovorin (7) 7
nsclc (7) 7
paclitaxel (7) 7
patients (7) 7
platinum (7) 7
product development (7) 7
proportional hazards models (7) 7
prospective studies (7) 7
protein kinase inhibitors - therapeutic use (7) 7
retrospective studies (7) 7
1st-line treatment (6) 6
cisplatin - administration & dosage (6) 6
colorectal neoplasms - pathology (6) 6
combined modality therapy (6) 6
fluorouracil (6) 6
growth-factor receptor (6) 6
irinotecan (6) 6
medicine, general & internal (6) 6
open-label (6) 6
pulmonary/respiratory (6) 6
receptor, epidermal growth factor - antagonists & inhibitors (6) 6
solid tumors (6) 6
young adult (6) 6
abridged index medicus (5) 5
angiogenesis (5) 5
antibodies, monoclonal - therapeutic use (5) 5
cancer research (5) 5
carcinoma, non-small-cell lung - genetics (5) 5
colorectal neoplasms - genetics (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 59 - 68
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 7, pp. 700 - 712
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9944, pp. 665 - 673
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 499 - 508
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 6, pp. 521 - 529
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 763 - 774
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 300 - 308
Summary Background Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head... 
Hematology, Oncology and Palliative Medicine | GEFITINIB | THERAPY | ONCOLOGY | KRAS | DOCETAXEL | III TRIAL | EGFR | Erlotinib Hydrochloride | Immunohistochemistry | Lung Neoplasms - drug therapy | Prospective Studies | Guanine - analogs & derivatives | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Early Termination of Clinical Trials | Receptor, Epidermal Growth Factor - metabolism | Carcinoma, Non-Small-Cell Lung - secondary | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Lung Neoplasms - enzymology | Europe | Kaplan-Meier Estimate | Treatment Outcome | Chi-Square Distribution | Pemetrexed | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Guanine - administration & dosage | Medical colleges | Care and treatment | Prognosis | Lung cancer | Oncology, Experimental | Clinical trials | Research | Lung cancer, Non-small cell | Antineoplastic agents | Antimitotic agents | Cancer patients | Chemotherapy | Erlotinib | Universities and colleges | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9699, pp. 1432 - 1440
Journal Article